NanoCon Newswire
July 18, 2006 (Skokie, Ill.) — NanoInk, Inc. announced today the appointment of Robert J. Janosky, as the Company’s president and chief operating officer. Mr. Janosky will be responsible for guiding NanoInk’s operations and will report to Cedric Loiret-Bernal, M.D., the Company’s chief executive officer.
Mr. Janosky brings over 35 years of operational experience and significant pharmaceutical manufacturing expertise to NanoInk. Most recently, he served as vice president, manufacturing at Cubist Pharmaceuticals, a publicly traded biopharmaceutical company focused on developing and commercializing anti-infective therapies for the acute care environment. Prior, Mr. Janosky was vice president, manufacturing at Warner Lambert and also served as the president and general manager of the company’s Puerto Rico location. Additionally he has held other senior management positions with Cardinal Health, Rhône Poulenc-Rorer and Bristol Myers. He received his B.S. in Science and Chemistry from Gannon University.
“Bob Janosky is a highly-regarded executive with an excellent track record at both small and large pharmaceutical companies. We believe his considerable manufacturing and operating experience will help drive NanoInk’s growth,” said Dr. Loiret-Bernal. “Equally important, his daily oversight of our operations will enable me to better focus on the current and long-term strategic and financial objectives of the Company.”
In accepting his appointment, Mr. Janosky said, “My key priority for NanoInk is to build long term relationships with existing and future customers with flawless execution. We have the talent and momentum to succeed, and I am enthusiastic to join the Company at this stage.”
About NanoInk NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the lifescience and semiconductor industries. With DPN, a patented and proprietary nanofabrication technology that allows for unmatched flexibility, accuracy and also its high-resolution Nanoencryption technology, NanoInk is able to offer its pharmaceutical customers innovative solutions to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products. Other key applications include nanoscale additive repair, and nanoscale rapid prototyping. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 100 issued or pending patents and patent applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, and the University of Illinois at Urbana-Champaign. For more information on products and services offered by NanoInk, Inc., see www.nanoink.net.
# # #
Contacts: David Gutierrez, Dresner Corporate Services, 312-780-7204, [email protected]
Sarah Komuniecki, Dresner Corporate Services, 312-780-7208, [email protected]